Global FFR as Prognosis in CAD Patients without Ischemia

Global fractional flow reserve (FFR) results from adding up FFR values of the three major coronary arteries. This figure represents the physiological atherosclerosis burden and can predict events at long term in patients without stenosis leading to ischemia.

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

This recent study published in JAHA looked at major cardiovascular events (death, infarction and revascularization) at 5 years in 1122 patients with no significant stenosis (lesions with FFR > 0.8 n=275) or presenting at least one significant lesion successfully treated (post PCI FFR > 0.8 n=847).

FFR was measured in the three main coronary arteries and these values were added to stratify patients into global FFR tertiles (low ≤ 2.80, intermediate between 2.80 and 2.88, and high ≥ 2.88).

Patients in the lowest tertile presented more events at 5 years compared against the intermediate and high tertiles (27.5% vs 22.0% and 20.9%, respectively; p=0.040).

The highest events rate in the group with low global FFR was driven mainly by more revascularization (16.4% vs 11.3% and 11.8%, respectively; p=0.038).


Read also: Sapien 3 Performs Well in “Jobs” for Which It Is Not Designed.


For each additional 0.1 FFR there was a significant reduction in total events (HR 0.988; CI 95%, 0.977 to 0.998; p=0.023), infarctions (HR 0.982; CI 95%, 0.966 to 0.998; p=0.032) and revascularization (HR 0.985; CI 95%, 0.972 to 0.999; p=0.040).

This is one of the studies that most clearly shows the concept of FFR as a continuous variable with a large spectrum of greys, as opposed to a binary variable below or over 0.8. 

Conclusion

Global FFR (the added FFR values of the three main cardiac arteries) is capable of predicting events at 5 years even in patients without ischemia driven by stenosis. Global FFR can be interpreted as the burden of physiological atherosclerosis.

JAHA-120-017729free

Original Title: Global Fractional Flow Reserve Value Predicts 5-Year Outcomes in Patients With Coronary Atherosclerosis But Without Ischemia.

Reference: Stephane Fournier et al. J Am Heart Assoc. 2020;9:e017729.  DOI: 10.1161/JAHA.120.017729.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....